A clinical pharmacology study of the novel, selective urate reabsorption inhibitor dotinurad in outpatients

BACKGROUND: Dotinurad is a novel, selective urate reabsorption inhibitor (SURI), which reduces serum uric acid levels by selective inhibition of the urate transporter 1 (URAT1). The Japanese guideline for the management of hyperuricemia and gout recommends that drug selection should be based on clas...

Descripción completa

Detalles Bibliográficos
Autores principales: Hosoya, Tatsuo, Furuno, Kazuki, Kanda, Shingo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066296/
https://www.ncbi.nlm.nih.gov/pubmed/32067130
http://dx.doi.org/10.1007/s10157-020-01857-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066296/
https://www.ncbi.nlm.nih.gov/pubmed/32067130
http://dx.doi.org/10.1007/s10157-020-01857-0

Ejemplares similares